NOMO-1 Xenograft Model Service for AML

The NOMO-1 cell line provides a robust and translationally relevant in vivo platform for investigating acute myeloid leukemia (AML), enabling researchers to explore leukemic progression and therapeutic sensitivities in a highly controlled environment. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision NOMO-1 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your AML drug discovery and development pipeline.

Overview of NOMO-1 Xenograft Model for AML

The NOMO-1 xenograft model is an established in vivo translational system widely utilized in hematological oncology research for the study of AML. By transplanting human NOMO-1 myeloblastic cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow homing kinetics, and peripheral blood pathophysiological profiles characteristic of clinical human leukemia.

Biologically, the NOMO-1 model is highly valued for its consistent engraftment profiles and predictable disease progression, which provide investigators with a reliable experimental window for evaluating complex dosing schedules and pharmacodynamics. This model preserves critical human myeloid molecular features, including lineage-specific marker expression and intracellular signaling pathways that drive blast expansion. Consequently, the NOMO-1 model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of novel small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Fig 1. KO of MSLN decreases NOMO-1 cell adhesion to ECM. (Faust JR, et al., 2026)

Cell Line Information: NOMO-1

The NOMO-1 cell line is derived from the peripheral blood of a patient diagnosed with AML. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable myeloblastic phenotype that serves as a robust proxy for hematological cancer research.

Our Services

Workflow of NOMO-1 Xenograft Model Construction

• Cell Culture & Quality Control: Human NOMO-1 cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains to support hematological engraftment) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability NOMO-1 cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or specific myeloid markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. NOMO-1 Xenograft Model Construction Workflow

Case Study - NOMO-1 Xenograft Model Development

A pre-clinical validation study was conducted using the NOMO-1 xenograft model to evaluate the therapeutic efficacy of a novel targeted inhibitor designed for AML. Following precision intravenous inoculation of human NOMO-1 cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our NOMO-1 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.